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Statement of Translational Relevance (max 150 words)  
Dysregulated pathways of kinase signaling, including those involving c-KIT and SRC family 
kinases (SFKs), play an important role in tumorigenesis. Dasatinib is an oral, small-molecule 
multi-kinase inhibitor of several SFKs as well as c-KIT, PDGFR, BCR-ABL, and ephrin 
receptor kinases. Although the benefits of dasatinib in patients with hematologic malignancies 
have been demonstrated previously, its activity in patients with solid tumors has yet to be 
established. This work is relevant to current and future anticancer drug therapy because our 
results show that dasatinib, a multikinase inhibitor with activity against SFKs, is acceptably 
well tolerated in patients with solid tumors with encouraging preliminary evidence of efficacy 
in patients with advanced refractory disease. Importantly the results of our study form the 
basis of dasatinib dosing for further clinical development in solid tumor oncology.  
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ABSTRACT 
Purpose: To determine the maximum tolerated dose (MTD), dose-limiting toxicity (DLT), 
and recommended phase II dose of dasatinib in metastatic solid tumors refractory to standard 
therapies or for which no effective standard therapy exists. 
Experimental Design : In this phase I, open-label, dose-escalation study, patients received 
dasatinib 35-160 mg twice daily (BID) in 28-day cycles, either every 12 hours for five 
consecutive days followed by two non-treatment days every week (5D2), or as continuous, 
twice-daily (CDD) dosing. 
Results: Sixty-seven patients were treated (5D2: n=33, CDD: n=34). The MTDs were 120 mg 
BID 5D2 and 70 mg BID CDD. DLTs with 160 mg 5D2 were recurrent grade 2 rash, grade 3 
lethargy, and one patient with both grade 3 prolonged bleeding time and grade 3 
hypocalcemia; DLTs with 120 mg BID CDD were grade 3 nausea, grade 3 fatigue, and one 
patient with both grade 3 rash and grade 2 proteinuria. The most frequent treatment-related 
toxicities across all doses were nausea, fatigue, lethargy, anorexia, proteinuria, and diarrhea, 
with infrequent hematologic toxicities. Pharmacokinetic data indicated rapid absorption, dose 
proportionality, and lack of drug accumulation. Although no objective tumor responses were 
seen, durable stable disease was observed in 16% of patients. 
Conclusion: Dasatinib was well tolerated in this population, with a safety profile similar to 
that observed previously in leukemia patients though with much less hematologic toxicity. 
Limited, though encouraging, preliminary evidence of clinical activity was observed. Doses 
of 120 mg BID (5D2) or 70 mg BID (CDD) are recommended for further studies in patients 
with solid tumors. 
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INTRODUCTION 
Dysregulated cell signaling through multiple kinases is associated with oncogenesis in many 
tumors. SRC-family kinases (SFKs), including SRC, YES, and FYN, are non-receptor 
tyrosine kinases with a critical role in cellular proliferation. Together with YES and FYN, 
SRC has an ubiquitous distribution with particularly high levels in platelets, neurons, 
osteoclasts and at epithelial cell-cell junctions (1,2). Expression of the remaining SFKs is 
restricted primarily to hematopoietic cells. SFKs are basic components of the cell signaling 
machinery and are involved in pathways regulating growth, survival, motility and adhesion 
(3). SFKs also promote several aspects of tumor progression and metastasis (4) and have a 
role in osteoclast function (5–7). SRC expression and/or activity are upregulated in a variety 
of human tumors (8–16). Additionally, more than 90% of gastrointestinal stromal tumors 
(GISTs) harbor activating mutations in either KIT or platelet-derived growth factor receptor-
alpha (PDGFRA) (17). 
 
Dasatinib is a kinase inhibitor with potent activity against several kinases, including SFKs, 
KIT, PDGFRA, EPHA2 and BCR-ABL in vitro (18,19). Dasatinib inhibits cellular Src 
autophosphorylation and cellular proliferation in a number of cancer cell lines in vitro, and 
has demonstrated in vivo anti-tumor efficacy in mice against a range of human tumor 
xenografts (19–21). In-vitro studies have demonstrated that dasatinib potently inhibits both 
wild-type and mutated KIT (22). Dasatinib has proven clinical efficacy in patients with 
chronic myelogenous leukemia (CML) and Philadelphia chromosome-positive acute 
lymphoblastic leukemia (Ph+ALL) (23–26).  
 
Consequently, we have performed a Phase I study with dasatinib in patients with advanced 
solid tumors that were refractory to standard therapies or for whom no effective standard 
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therapy existed. The primary objective of this study was to establish the maximum tolerated 
dose (MTD), dose-limiting toxicity (DLT), and recommended phase II dose of dasatinib. 
Secondary objectives included evaluation of the safety, tolerability, and plasma 
pharmacokinetics of dasatinib, and assessing any preliminary evidence of anti-tumor efficacy.  
 
PATIENTS AND METHODS 
Patients and Eligibility Criteria 
This was a non-randomized, open-label, Phase I, dose-escalation study conducted in 
accordance with the International Conference on Harmonization Good Clinical Practice (ICH 
GCP) with the ethical principles of the current Declaration of Helsinki and approved by the 
Research Ethics Committee at each of the participating institutions. All patients provided 
written, informed consent prior to performing any study-related procedures. 
 
All patients entered into this study had a verified advanced solid malignancy, refractory to 
conventional therapy or for which there was no effective therapy. Eligible patients were aged 
e18 years with an Eastern Cooperative Oncology Group (ECOG) performance status 0-1. 
They should not have received chemotherapy, immunotherapy, or radiotherapy within 4 
weeks of entering the study (6 weeks for nitrosoureas, mitomycin C, and liposomal 
doxorubicin) and at least 2 weeks must have elapsed since exposure to other kinase inhibitors. 
Eligibility criteria also included adequate hematologic, hepatic, and renal function, serum 
potassium and magnesium within the institution’s normal range, corrected serum calcium 
above the institution’s lower limit of normal, and either a bleeding time which was less than 
the institution’s upper limit of normal or a platelet aggregometry test within normal limits.  
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Patients were excluded if they had received prior radiotherapy to e25% of the bone marrow-
containing skeleton, or if they had uncontrolled or significant cardiovascular disease, known 
brain metastasis, prolonged QT syndrome or QTc >450 msec, history of a significant bleeding 
disorder, vasculitis, or a significant bleeding episode from the GI tract in the preceding 6 
months. Patients who were pregnant or breastfeeding, or who were of childbearing potential 
but unwilling or unable to use adequate contraception were also excluded. Prohibited 
medications included those known to increase the risk of Torsades de Pointes, irreversible 
inhibitors of platelet function and anticoagulants.  
 
Treatment Administration 
Pre-treatment evaluation included a complete history and clinical examination, vital signs, 
assessment of performance status, full blood count, biochemical profile, coagulation screen, 
bleeding time or platelet aggregometry, fasting cholesterol, triglycerides, and glucose, CD4+ 
T-cell count, creatine kinase (CK), CK-MB, troponin I and T, thyroid-stimulating hormone 
(TSH), urinalysis, chest x-ray, and pregnancy test. Electrocardiograms (EKGs) were 
performed in triplicate 1-3 days prior to study treatment. Relevant radiologic studies to 
evaluate sites of disease were performed within 3 weeks prior to dosing on day 1.  
 
Dasatinib was administered orally on an empty stomach in 28-day treatment cycles either 
every 12 hours for 5 consecutive days followed by two non-treatment days every week (5D2 
schedule), or continuously, twice-daily (CDD schedule). No concomitant anti-cancer therapy 
was permitted. Hematopoietic growth factors and erythropoietin were permitted, but not 
within the first 28 days of drug administration during which time DLTs were assessed.  
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The dasatinib starting dose (35 mg BID) was based on prior clinical experience from studies 
in hematologic malignancies (27) and was escalated in subsequent dose cohorts until the 
MTD was determined. Once the MTD was reached on the 5D2 schedule, subsequent patients 
were enrolled on the CDD schedule, with a starting dose two levels below the 5D2 MTD. 
Dose escalation on the CDD schedule continued until the CDD MTD was reached. Once the 
MTD had been defined, an additional cohort of up to 15-20 patients was recruited.  
 
Study treatment continued until progressive disease (PD), death, pregnancy, withdrawal of 
consent, or unacceptable toxicity. Patients initially treated on the 5D2 schedule had the option 
of crossing over to the CDD schedule at the investigator’s discretion. All patients were 
followed for a minimum of 30 days after the last dose of study therapy, or until recovery from 
any treatment-related toxicity.  
 
Evaluation of Toxicity 
Toxicity was graded using the National Cancer Institute Common Toxicity Criteria (NCI-
CTCAE) Version 3.0. Physical examinations and assessment of ECOG performance status 
were performed weekly. Laboratory assessments, similar to those performed pre-treatment, 
were also performed at regular intervals. EKGs were performed in triplicate 10 minutes pre-
administration and 1, 2, 3, 4, 6, 8, and 10 hours post-administration on day 1, once between 
days 3-5, and once between days 24-26, of cycle 1. Toxicity assessments of subjects who 
remained on study with no dose reductions or interruptions e3 months were subsequently 
performed every 4 weeks.  
 
DLT was defined as grade 4 neutropenia for e5 consecutive days; febrile neutropenia [defined 
as absolute neutrophil count (ANC) <1000/mm3 with temperature ≥38.5ºC]; 
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thrombocytopenia (d25,000 cells/mm3 or bleeding requiring platelet transfusion); QTc interval 
of e500 msec; grade 3-4 nausea, vomiting, or diarrhea despite maximal prophylaxis and 
intervention; any other grade e3 non-hematologic event except alopecia or fatigue (unless the 
fatigue were recurrent); drug-related toxicity that delayed scheduled re-treatment for >14 
days; and any grade of toxicity requiring dose reduction or discontinuation of study drug 
within the DLT assessment period. Description of DLTs, dose-escalation decisions, and 
determination of the MTD were based on toxicities occurring within the first 4 weeks of drug 
administration. Cumulative toxicities were recorded at all dose cohorts.  
 
At least three patients were enrolled at each dose cohort. If a DLT occurred, the cohort was 
expanded up to a maximum of six patients. The MTD was defined as the dose level below 
which >1 out of 3 or e2 of 6 patients experienced a DLT. Intrapatient dose escalation was 
permitted if the maximum toxicity during prior cycles of therapy was grade 2 or less and if d1 
DLT was observed in cycle 1 in 3-6 patients who had completed 4 weeks of study drug at the 
next higher dose level.  
 
Dose Delays and Modifications 
Dose delays and modifications were performed on the basis of toxicity. Re-treatment after 
dose interruption could be delayed for up to 14 days to allow recovery from any toxicity. 
Dose reductions were to the previous dose level or by 25%, whichever was larger. Following 
dose interruption for non-hematologic toxicities, dosing was recommenced when toxicities 
had resolved to grade 1 or baseline levels. Dosing was interrupted for any grade 2 non-
hematologic toxicity (except alopecia or fatigue) thought to be related to the study drug, with 
dose reduction after recovery from the second occurrence. Dosing was interrupted, with 
subsequent reduction on recovery, following the first occurrence of grade 2 neuropathy and 
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grade 3 nausea, vomiting, or diarrhea, despite adequate/maximal intervention and/or 
prophylaxis. For QTc prolongation e500 msec but <530 msec by both the Bazett and 
Fridericia methods which resolved without any associated clinically significant arrhythmia, 
study drug was recommenced with a dose reduction after a minimum of 2 days interruption of 
dosing. Dosing was also interrupted following grade 3/4 neutropenia or thrombocytopenia, 
with dose reductions implemented depending on time to recovery and severity. Patients who 
had their dose of dasatinib reduced due to toxicity did not have subsequent dose increases. 
Patients who developed recurrent toxicity despite dose reduction could remain on study after a 
second dose reduction at the discretion of the investigators. However, study drug was 
discontinued after the first occurrence of grade 4 non-hematologic toxicity, > grade 3 
neuropathy, or QTc prolongation e530 msec.   
 
Disease Evaluation and Objective Response Assessment 
Tumor size was evaluated by computed tomography (CT) or magnetic resonance imaging 
(MRI), chest X-ray, and by physical examination in patients before starting study therapy. 
Assessments were repeated after every two cycles of treatment, after every 12 weeks for 
patients who had been on study treatment for 24 weeks and at the end of treatment. Responses 
to treatment were defined using the modified World Health Organization criteria (28), and all 
analyses performed on an intention-to-treat basis.  
 
Pharmacokinetics 
Blood samples for pharmacokinetic analysis were collected predose, 30 minutes, and 1, 1.5, 2, 
3, 4, 5, 6, 8, and 10 hours post dose on the morning of day 1, once on days 3-5, and once on 
days 24-26 during Cycle 1. Samples were assayed for dasatinib and BMS-606181, the N-
oxide metabolite of dasatinib, concentrations by Bristol-Myers Squibb and Cedra Corporation 
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(Texas, United States) using a cross-validated liquid chromatography tandem mass 
spectrometry method. Pharmacokinetic parameters were derived from plasma concentration–
time data by a non-compartmental method, using KineticaTM Basic Version 4.4.1 in the 
eToolbox (version 2.6.1; Thermo Electron Corporation, Pennsylvania, United States). These 
included the maximal plasma concentration (Cmax) and time of Cmax (tmax) (obtained from 
experimental observations), the apparent plasma elimination half-life (t1/2) (calculated as 
ln2/Lz, where Lz was the absolute value of the slope of the terminal log-phase), the apparent 
oral clearance (CLo), the apparent volume of distribution in the terminal phase (Vz/F), and 
the area under the curve (AUC) within the dosing interval (12 hours) [AUCTAU]. AUCTAU 
were calculated using the mixed log-linear trapezoidal algorithm in KineticaTM. Dose-
proportionality was assessed by performing linear regression analyses on logAUC versus logdose 
for day 8 and day 26 with combined data from 5D2 and CDD schedules.  
 
Pharmacodynamic Studies 
The amount of phosphorylated SRC (pSRC) in peripheral blood cells was determined as a 
surrogate biomarker of kinase activity by ELISA as previously described (29). Additionally, 
FDG-PET imaging analyses were performed in a subset of 35 patients at baseline prior to 
treatment and periodically while receiving dasatinib. Metabolic response was assessed based 
on criteria established by the European Organization for Research and Treatment of Cancer 
(EORTC) (30). A quantitative analysis of the PET imaging as a pharmacodynamic readout for 
this study is beyond the scope of this report and will be presented in a separate manuscript.  
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RESULTS 
Patient characteristics 
Sixty-seven patients were enrolled (5D2, n=33; CDD, n=34). All 67 patients were included in 
the analysis of toxicity, with 48 patients evaluable for response. Patient baseline 
characteristics are summarized in Table 1; a large percentage of the trial consisted of patients 
with advanced GIST resistant to other kinase inhibitors. Two patients (3%), both in the CDD 
group, were alive with stable disease lasting >90 days at study closure and continuing to 
receive dasatinib. The median time from cancer diagnosis to study start was 43.1 months. 
Prior cancer treatment included surgery (n=67), systemic therapy/chemotherapy (n=63), 
radiotherapy (n=19), hormonal/immunotherapy/biological therapy (n=4), or other 
investigational agents (n=8). Most patients had received more than one prior systemic therapy 
regimen including nine (13%) patients who had received two regimens, 13 (19%) three 
regimens, 19 (28%) four regimens and 11 (16%) five or more regimens.  
 
Patients received dasatinib in nine dose cohorts: 35, 50, 70, 90, 120 and 160 mg BID (5D2) 
and 70, 90, and 120 mg BID (CDD), with a subsequent expanded dose cohort enrolled at an 
intermediate dose level (100 mg BID, CDD) (Table 2). Duration of therapy was greater for 
patients on the 5D2 schedule compared with those on the CDD schedule for all dose cohorts. 
In contrast, dose intensity was greater for patients on the CDD schedule.  
 
Toxicity  
DLTs were observed in six of 26 evaluable patients with the 5D2 schedule, and in 11 of 27 
evaluable patients with the CDD schedule. On the 5D2 schedule, one of seven evaluable 
patients enrolled at 35 mg BID reported a DLT of grade 3 dehydration and anorexia, one of 
six patients enrolled at 90 mg BID reported grade 3 dehydration and hyponatremia, and one of 
13 
nine patients enrolled at 120 mg BID reported grade 3 tumor lysis syndrome. None of the 
patients enrolled at 50 or 70 mg BID had a DLT. Of four evaluable patients enrolled at 160 
mg BID, three reported DLTs: grade 2 rash that interrupted, grade 3 lethargy, and one patient 
with both grade 3 prolonged bleeding time and grade 3 hypocalcemia. 
 
On the CDD schedule, none of the three patients enrolled at 70 mg BID reported DLTs. At the 
90 mg BID dose level, DLTs were observed in two of seven patients (grade 3 proteinuria and 
grade 2 rash in 1 patient, and grade 1 cognitive impairment with grade 2 somnolence, altered 
taste, slurred speech and unsteady gait). During the dose-escalation part of the study, it had 
been unclear if the grade 1 cognitive impairment with grade 2 somnolence was related to the 
study drug and this patient was therefore replaced and the subsequent dose-escalation 
proceeded as per protocol. However, based on the observed toxicities at 100 and 120 mg BID 
(CDD), it was concluded retrospectively that this event had been drug-related and was dose 
limiting. The first four patients at the intermediate (100 mg BID) dose level reported no 
DLTs. However, when this cohort was further expanded, six of the 13 patients reported DLTs, 
including one patient who developed grade 2 myocardial toxicity and EKG T-wave inversion, 
and grade 4 elevation of cardiac troponin. The myocardial toxicity and elevated cardiac 
troponin resolved following appropriate treatment. Other DLTs in this cohort included grade 3 
dyspnea, grade 3 constipation, grade 2 proteinuria, grade 4 fatigue and grade 3 lethargy. At 
the 120 mg BID dose level, three of four patients reported DLTs, which were grade 3 nausea, 
grade 3 fatigue, and one patient with both grade 3 rash and grade 2 proteinuria. Consequently, 
the MTDs (and recommended doses) were defined as 120 mg BID on the 5D2 schedule (DLT 
in 1/6 patients) and 70 mg BID on the CDD schedule (no DLTs).  
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Cumulative Toxicity 
Cumulative toxicity (worse grade per patient, all cycles) is summarized in Tables 3 and 4. 
Hematologic toxicity was reported in four patients. Two patients on the 5D2 schedule who 
had grade 1-2 anemia at baseline developed grade 3 anemia while on study drug (50 mg BID, 
70 mg BID). On the CDD schedule, one patient had grade 4 neutropenia (120 mg BID) and 
another grade 3 anemia (100 mg BID).  
 
On the 5D2 schedule, the most common treatment-related non-hematologic toxicities were 
nausea (64%), and fatigue (42%) (Table 3). One patient on the 5D2 schedule (50 mg BID) 
experienced moderate QTc prolongation and EKG ST segment changes (grade 2). On the 
CDD schedule, the most common treatment-related non-hematologic toxicities were nausea 
(53%), and anorexia (50%) (Table 4). Pleural effusion considered by the study investigator to 
be related to dasatinib treatment was observed in three patients on the CDD schedule. All 
were grade 1-2 and occurred at the 70 mg (n=2) or 90 mg (n=1) BID dose level. The majority 
of non-hematologic events were grade 1-2. However, three grade 4 events were observed 
(suicidal depression [35 mg BID, 5D2], fatigue [100 mg BID, CDD], and elevated cardiac 
troponin [100 mg BID, CDD]). The occurrence of non-hematologic toxicities did not appear 
to be dose related with either the 5D2 or CDD schedules.  
 
Thirteen patients discontinued treatment due to drug-related toxicity: three patients on the 
5D2 schedule (suicidal ideation withdepression; vomiting; and prolonged bleeding time) and 
ten patients on the CDD schedule (nausea, headache, vomiting, gait disturbance, cognitive 
disorder, dysarthria, dysgeusia, somnolence, fatigue, proteinuria, cardiotoxicity, constipation, 
EKG T-wave inversion, increased troponin, and anorexia). 
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Ten patients died during the study or within 30 days of their last dose of dasatinib, and eight 
died more than 30 days after their last dose of dasatinib. All of these deaths were due to 
disease progression; one patient died from vomiting and gastrointestinal bleeding which was 
considered to be most likely due to disease progression, although a possible contribution from 
the study drug could not be excluded. 
 
Dose Interruptions and Dose Modifications 
Dose reductions were necessary for 19% of patients and were more frequent in the CDD 
group (n=9, 27%) than in the 5D2 group (n=4, 12%). The most common reason for first dose 
reduction was hematologic (3%; 5D2, n=1; CDD, n=1) or non-hematologic (8%; 5D2, n=3; 
CDD, n=2) toxicity. Hematologic toxicities requiring first dose reduction were 
thrombocytopenia in the 5D2 group (160 mg BID) and anemia in the CDD group (100 mg 
BID). Non-hematologic toxicities reported by the investigators requiring first dose reduction 
in the 5D2 group were elevated serum glutamic pyruvic transaminase (SGPT) levels (35 mg 
BID) and rash and grade 3 hypocalcemia (160 mg BID). Non-hematologic toxicities in the 
CDD group were grade 2 rash (n=1; 90 mg BID), and fatigue (n=1; 100 mg BID). 
 
Dose interruptions for toxicity were necessary for 28 patients (42%), and were more frequent 
in the CDD group (n=17) compared with the 5D2 group (n=11). Dose interruptions were most 
commonly the result of non-hematologic (31%; 5D2, n=6, CDD, n=15) rather than 
hematologic (3%; 5D2, n=1, CDD, n=1) toxicity. Non-hematologic toxicities reported by the 
investigators requiring first dose interruption in the 5D2 group included rectal bleeding/pain 
(70 mg BID), and grade 3 hypocalcemia (160 mg BID). Non-hematologic toxicities reported 
by the investigators requiring first dose interruption in the CDD group included patient 
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undergoing laser therapy (70 mg BID), dyspnea, shortness of breath, proteinuria and, fatigue 
(100 mg BID) and rash (120 mg BID).   
 
The median time to first dose reduction/interruption due to toxicity was 12 days [5D2 = 10 (2-
208) days; CDD = 12 (2–56) days]. The median length of dose interruptions due to toxicity 
was 7 days [5D2 = 8 (3-12) days; CDD = 5.5 (3-19) days]. 
 
Antitumor Activity 
There were no observed objective tumor responses. Eleven patients [including GIST (three 
patients), colon, melanoma, biliary tract, epithelial sarcoma, small bowel carcinoma, 
myoepithelioma, thigh sarcoma, and renal cell cancer; 16%] had RECIST-defined stable 
disease as their best response including seven of 33 (21%) of patients on the 5D2 schedule 
and four of 34 (12%) on the CDD schedule. The median duration of stable disease in these 
patients was 3.6 months (range 1.7-23.6).  
 
Similar findings were observed when comparing the metabolic response on 18FDG-PET 
imaging of individual lesions and the overall metabolic response of patients. Only four 
patients (12.9%) demonstrated an early metabolic partial response (PR) during the first week 
of treatment with dasatinib. However, by the end of Cycle 1 the proportion of patients with 
metabolic PR was nearly twice as large (23.8%). A similar proportion of patients with 
metabolic PR was observed at the end of Cycle 2 (25%).  
 
There was high variability in the pSrc assay using peripheral blood cells and, although pSrc 
inhibition was observed, a dose-response trend could not be determined (data not shown).  
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Pharmacokinetic Analyses  
The plasma concentration–time curves at steady-state (Day 26) are shown in Figure 1. 
Dasatinib was detectable in plasma 30 minutes after oral administration and reached Cmax at 
median Tmax values of 0.5-3.1 hours. The AUCTAU increased approximately proportionally 
with dose, the slope (90% CI) being 1.08 (90% CI: 0.63, 1.54) on Day 8 and 1.07 (90% CI: 
0.63, 1.51) on Day 26. The Cmax and AUCTAU values on Days 8 and 26 were similar, 
suggesting no clinically relevant accumulation on repeated dosing. Across the range of 35-
160 mg BID, the mean t1/2 of dasatinib was consistent on Days 8 and 26. Although consistent 
across the dose groups, there was considerable variability in both CLo and Vz/F.  
 
BMS-606181 was rapidly formed in subjects with metastatic tumors and is considered a 
minor metabolite of dasatinib. The metabolite-to-parent ratio unadjusted for molecular weight 
difference (which was less than 10%) ranged from less than 1% to 13%.  
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DISCUSSION 
Dasatinib potently inhibits several kinases, including KIT, PDGFRA, EPHA2, and BCR-ABL 
in addition to SFKs in vitro. Specific somatic mutations in the KIT gene resulting in kinase 
activation are implicated in the pathogenesis of GIST (31), and KIT dysregulation is also 
implicated in the pathobiology of a number of other tumor types including small cell lung 
carcinoma and certain melanomas. Similarly, dysregulation of expression and activation of 
the PDGF ligand and receptor systems is implicated in many forms of solid tumors including 
glioblastoma and prostate cancer (32). Furthermore, EPHA2 may promote angiogenesis (33), 
enhance tumor cell motility, invasion and metastasis (34, 35), and is over-expressed in 
melanoma and in several solid tumors.  
 
In this study, the recommended doses of dasatinib for phase II development appeared to be 
schedule-dependent: 120 mg BID for the 5D2 schedule, and 70 mg BID for the CDD 
schedule. A dose of 70 mg BID on a continuous administration schedule is currently approved 
for second-line treatment of patients with accelerated-phase CML (CML-AP), myeloid or 
lymphoid blast-phase CML (CML-BP), or Ph+ALL, and is well tolerated in these patients 
(23, 24, 26).  
 
The DLTs in this study were recurrent grade 2 rash requiring dose modification, grade 3 
lethargy, grade 3 prolonged bleeding time and grade 3 hypocalcemia with the 5D2 schedule, 
and grade 3 nausea, grade 3 fatigue, and 1 patient with both grade 3 rash and grade 2 
proteinuria with the CDD schedule. The most frequent cumulative toxicities in this present 
study were non-hematologic including diarrhea, nausea, fatigue, and lethargy. Other toxicities 
included anorexia, although this may have been secondary to nausea or other gastrointestinal 
toxicities in several cases, proteinuria and dyspnea. These toxicities were manageable with 
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dose interruption and reduction. However, hematologic toxicity was uncommon in this study 
with only one episode of grade 4 neutropenia, and no evidence of thrombocytopenia although 
prolonged bleeding time was observed as a DLT in one patient. In contrast, in the Phase I 
study of dasatinib in patients with CML or Ph+ALL intolerant or resistant to imatinib (27), 
grade 3 or 4 neutropenia occurred in 45% of patients with chronic-phase disease (CML-CP) 
and in 89% of patients with CML-AP, CML-BP, or Ph+ALL, although 55% of the latter 
group had grade 3 or 4 myelosuppression at study entry. Similarly, grade 3 or 4 
thrombocytopenia occurred in 35% of patients with CML-CP and in 80% of patients with 
CML-AP, -BP, or Ph+ALL (27). However, the contrasting hematologic toxicities observed 
between this study and that reported by Talpaz and colleagues is most likely due to either the 
result of the action of dasatinib against Ph+ leukemia cells or due to the disease-related 
compromised bone marrow function in the patients in the latter study. Dose interruptions and 
dose reductions (42% and 19% of patients respectively) were also less common in this study, 
and mostly due to non-hematologic toxicities. 
 
The role of SRC-dependent signaling on lymphovascular permeability is of great interest, and 
pleural effusion has been reported previously with dasatinib (27). In leukemic patients, pleural 
effusion is adequately managed by dose interruption/reduction and appropriate medical 
intervention (36). Moreover, findings from a trial comparing 70 mg BID dosing with 100 mg 
once-daily (QD) dosing in patients with CML-CP showed that the QD schedule improved 
tolerability, including reducing the occurrence of pleural effusion, while maintaining efficacy 
(37). In the present study, pleural effusion was infrequent with only two patients developing 
pleural effusion and both were grade 1/2. It appears that pleural effusions are observed less 
frequently with dasatinib in patients with solid tumors than in patients with hematologic 
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malignancies [35%; grade 3 or 4 in 17%] (38), although the reasons for this observation are 
unclear.  
 
Preliminary evidence suggests that dasatinib is not directly cardiotoxic per se, unlike other 
kinase inhibitors such as imatinib, sunitinib, and nilotinib, which have more profound in vitro 
effects on cardiac tissue (39). Although QT prolongation has been reported with dasatinib 
(27), extensive serial electrocardiographic monitoring demonstrated only one case of QTc 
prolongation (grade 2) in this study. The increase was moderate (e455 msec and d490 msec 
by the Bazett method) and resolved with a temporary dose reduction. Nevertheless, screening 
for patients at risk of QT prolongation is recommended before starting dasatinib therapy. 
Dose-limiting cardiac toxicity was observed in one patient in this study (grade 2 myocardial 
toxicity and EKG T-wave inversion, and grade 4 elevated cardiac troponin) which was 
reversible. Asymptomatic grade 1 or 2 hypocalcemia was noted in about 60% of the patients 
treated with dasatinib for hematologic malignancies (27). We observed one episode of grade 3 
hypocalcemia in this current study (dose limiting at 160 mg BID 5D2 schedule). This is most 
likely due to the key role of Src in osteoclast formation, activation, and survival (reviewed in 
Boyce et al (40)), raising the intriguing notion that dasatinib might justifiably be studied for 
the management of metastatic bone disease.  
 
Although studies suggest an immunosuppressant effect for dasatinib (41), there have been no 
indications of an increased susceptibility to infection following dasatinib in patients with 
CML. In this study hematologic toxicity was rare. Lymphopenia (grade 2) was reported for 
one patient (120 mg BID, 5D2) and was resolved by dose interruption.  
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The pharmacokinetic data suggest that there is no long-term drug accumulation. Although the 
small number of evaluable patients used for this analysis resulted in substantial variance, the 
data suggest rapid absorption and dose proportionality. In vitro studies of the activity of 
dasatinib metabolites, including BMS-606181, against SRC and BCR-ABL suggest that 
dasatinib metabolites do not contribute significantly toward in vivo activity (42). Further 
pharmacokinetic modeling will be required to determine whether the levels of drug achieved 
in this study are sufficient to inhibit specific kinases. 
 
No objective responses were observed in this study. However, this study was performed in 
patients with advanced, treatment-refractory solid tumors, in whom objective responses might 
not be observed despite an optimal biological effect on the proposed drug targets. The 
observation of stable disease in 16% of patients is encouraging, particularly as disease 
stabilization appeared durable, lasting for over 90 days in several patients, including stable 
disease for approximately 2 years in a patient with refractory metastatic melanoma. In 
addition, stable disease was observed in three of the 19 patients with GIST, lasting for more 
than three months in one of these patients. Two of these three patients with GIST had also 
received prior treatment with imatinib. These preliminary observations suggest dasatinib may 
have differential activity in patients with GIST compared to other available kinase inhibitors, 
similar to the distinctive clinical activity of dasatinib observed in CML patients (25). Gain-of-
function mutations of KIT are a critical oncogenic contributing factor to the malignant 
phenotype of most GISTs (43). In vitro data with dasatinib show that it potently inhibits both 
wild-type and mutated KIT, including inhibiting imatinib-resistant KIT activation loop 
mutants (22). It is unclear why more patients on the 5D2 schedule had stable disease than 
patients on the CDD schedule. 
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PET scan changes and biomarkers may act as additional indicators of a pharmacodynamic and 
meaningful biological response with dasatinib. A metabolic PR was observed in 23.8% of a 
subset of 35 patients at the end of cycle 1 and in 25% at the end of cycle 2. These results will 
be discussed more fully in a separate communication. The preliminary effects of dasatinib on 
levels of the biomarker pSRC were reported by Luo et al using data from the study reported 
here and from a phase I study in patients with CML (29). The results showed that with BID 
dosing, pSrc inhibition was dose dependent across the dosing range (25-160 mg BID). 
Inhibition also directly correlated with dasatinib plasma concentration, with maximal 
inhibition achieved at approximately 2.5 hours (29). Upon database closure and data analysis 
of the study reported herein, there was a higher variability of the assay than previously found, 
and although pSrc inhibition was observed, a dose-response trend could not be determined.  
 
In conclusion, this is the first clinical study of an inhibitor of SFKs in patients with solid 
tumors. Dasatinib was well tolerated and hematologic toxicities were infrequent. Doses of 120 
mg BID on the 5D2 schedule or 70 mg BID on a continuous administration schedule are 
recommended for future studies. Encouraging preliminary evidence of efficacy was observed, 
and further studies are required in patients with solid tumors.  
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TABLES AND FIGURES 
Table 1. Baseline demographic and clinical characteristics 
 
 Dasatinib schedule  
5D2 
(n = 33) 
CDD 
(n = 34) 
Total 
(N = 67) 
Median age, years (range) 56 
(32-81) 
59 
(31-82) 
57 
(31-82) 
Gender     
 Male 20 (60.6%) 18 (52.9%) 38 (56.7%) 
 Female 13 (39.4%) 16 (47.1%) 29 (43.3%) 
Baseline ECOG score     
 0 18 (54.5%) 14 (41.2%) 32 (47.8%) 
 1 15 (45.5%) 20 (58.8%) 35 (52.2%) 
Tumor type    
 GIST 17 (51.5%) 2 (5.9%) 19 (28.4%) 
 Colon 2 (6.1%) 6 (17.6%) 8 (11.9%) 
 Sarcoma 4 (12.1%) 4 (11.8%) 8 (11.9%) 
 Melanoma 3 (9.1%) 2 (5.9%) 5 (7.5%) 
 Rectum 2 (6.1%) 3 (8.8%) 5 (7.5%) 
 Gastric  1 (3.0%) 3 (8.8%) 4 (6.0%) 
 Mesothelioma 0 3 (8.8%) 3 (4.5%) 
 MPN sheath tumor 1 (3.0%) 1 (2.9%) 2 (3.0%) 
 Ovary 0 1 (2.9%) 1 (1.5%) 
 Other*  3 (9.1%) 9 (26.5%) 12 (17.9%) 
*Other tumors reported by study investigators were desmoid tumor, biliary tract, small bowel 
(5D2); adenoid cystic carcinoma, myoepithelioma, chordoma, squamous cell carcinoma of 
left pinna, meningioma, chromophobe renal cell carcinoma, medullary thyroid, endometrial 
and breast (CDD). 
 
Abbreviations: ECOG, Eastern Cooperative Oncology Group; GIST, gastrointestinal stromal 
tumor; MPN, malignant peripheral nerve sheath tumor. 
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Table 2. Overview of dasatinib treatment 
 
Dasatinib cohort (n) 
Treatment duration 
Median (range), 
months 
Treatment duration 
excluding interruptions  
Median (range), 
months 
Total dose 
Median (range), 
mg 
Net dose intensity, 
mg/day* 
5D2 schedule     
 35 mg (n = 7) 0.9 (0.1-7.4) 0.9 (0.1-7.2) 1400 (210.0-14190) 54 (40-70) 
 50 mg (n = 3) 4.0 (1.1-5.0) 3.7 (1.1-5.0) 7850 (2450-14110) 75 (71-93) 
 70 mg (n = 4) 2.8 (1.1-4.1) 2.8 (1.1-3.8) 8750 (3430-11480) 103 (99-104) 
 90 mg (n = 6) 2.1 (0.7-3.6) 1.9 (0.7-3.6) 7560 (3330-14400) 132 (126-180) 
 120 mg (n = 9) 1.1 (0.2-4.4) 0.9 (0.2-4.4) 4800 (1080-23160) 182 (157-216) 
 160 mg (n = 4) 4.0 (1.3-23.8) 3.7 (0.8-21.6) 20875 (3970-84720) 152 (129-225) 
CDD schedule     
 70 mg (n = 5) 1.0 (0.1-9.6) 0.8 (0.1-9.6) 3500 (170-40950) 140 (85-140) 
 90 mg (n = 7) 1.7 (0.6-18.3) 1.6 (0.3-16.9) 8550 (1710-90630) 177 (149-182) 
 100 mg (n = 17) 1.2 (0.1-12.9) 0.8 (0.1-12.5) 4700 (400-75800) 197 (157-216) 
 120 mg (n = 5) 0.3 (0.2-1.8) 0.2 (0.2-1.8) 1440 (1080-21720) 236 (197-240) 
*Net dose intensity = cumulative total dose divided by treatment duration (excluding interruption) per patient 
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Table 3. Treatment-related non-hematologic toxicities occurring in e10% of patients on the 5D2 dosing schedule (Gr = Grade) 
 
 35 mg (n=7) 50 mg (n=3) 70 mg (n=4) 90 mg (n=6) 120 mg (n=9)  160 mg (n=4) Overall (N=33) 
Event, n (%) Gr 1-2 Gr 3-4 Gr 1-2 Gr 3-4 Gr 1-2 Gr 3-4 Gr 1-2 Gr 3-4 Gr 1-2 Gr 3-4 Gr 1-2 Gr 3-4 Gr 1-2 Gr 3-4 
Nausea 4 (57) 0 (0) 1 (33) 0 (0) 3 (75) 0 (0) 1 (17) 0 (0) 7 (78) 1 (11) 4 (100) 0 (0) 20 (61) 1 (3) 
Fatigue 3 (43) 0 (0) 2 (66) 0 (0) 3 (75) 0 (0) 3 (50) 0 (0) 2 (22) 0 (0) 1 (25) 0 (0) 14 (42) 0 (0) 
Diarrhea 3 (43)  1 (14) 1 (33) 0 (0) 1 (25) 0 (0) 1 (17) 0 (0) 4 (44) 0 (0) 3 (75) 0 (0) 13 (39) 1 (3) 
Vomiting 2 (29) 0 (0) 1 (33) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 4 (44) 1 (11) 2 (50) 0 (0) 9 (27) 1 (3) 
Anorexia 1 (14) 1 (14) 1 (33) 0 (0) 2 (50) 0 (0) 1 (17) 0 (0) 1 (11) 0 (0) 2 (50) 1 (25) 8 (24) 2 (6) 
Lethargy 0 (0) 0 (0) 1 (33) 0 (0) 0 (0) 0 (0) 2 (33) 0 (0) 2 (22) 0 (0) 2 (50) 1 (25) 7 (21) 1 (3) 
Headache 1 (14) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 1 (17) 0 (0) 2 (22) 0 (0) 1 (25) 0 (0) 5 (15) 0 (0) 
Pyrexia 1 (14) 0 (0) 1 (33) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 1 (11) 0 (0) 1 (25) 0 (0) 4 (12) 0 (0) 
Chills 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 1 (11) 0 (0) 3 (75) 0 (0) 4 (12) 0 (0) 
Proteinuria 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 1 (11) 0 (0) 2 (50) 1 (25) 3 (9) 1 (3) 
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Table 4. Treatment-related non-hematologic toxicities occurring in e10% of patients on the CDD dosing schedule (Gr = Grade) 
 70 mg (n=5) 90 mg (n=7) 100 mg (n=17)  120 mg (n=5) Overall (N=34) 
Event, n (%) Gr 1-2 Gr 3-4 Gr 1-2 Gr 3-4 Gr 1-2 Gr 3-4 Gr 1-2 Gr 3-4 Gr 1-2 Gr 3-4 
Nausea 4 (80) 0 (0) 4 (57) 0 (0) 7 (41) 0 (0) 2 (40) 1 (20) 17 (50) 1 (3) 
Anorexia 2 (40) 0 (0) 4 (57) 0 (0) 9 (53) 0 (0) 2 (40) 0 (0) 17 (50) 0 (0) 
Fatigue 1 (20) 0 (0) 2 (29) 0 (0) 8 (47) 1 (6) 2 (40) 1 (20) 13 (38) 2 (6) 
Diarrhea 1 (20) 0 (0) 3 (43) 0 (0) 6 (35) 0 (0) 1 (20) 0 (0) 11 (32) 0 (0) 
Lethargy 2 (40) 0 (0) 3 (43) 0 (0) 2 (12) 1 (6) 0 (0) 0 (0) 7 (21) 1 (3) 
Vomiting 1 (20) 0 (0) 3 (43) 0 (0) 3 (18) 0 (0) 0 (0) 0 (0) 7 (21) 0 (0) 
Headache 2 (40) 0 (0) 0 (0) 0 (0) 3 (18) 0 (0) 1 (20) 0 (0) 6 (18) 0 (0) 
Proteinuria 0 (0) 0 (0) 0 (0) 1 (14) 4 (24) 0 (0) 1 (20) 0 (0) 5 (15) 1 (3) 
Rash 0 (0) 0 (0) 2 (29) 0 (0) 3 (18) 0 (0) 0 (0) 1 (20) 5 (15) 1 (3) 
Pruritus 0 (0) 0 (0) 1 (14) 0 (0) 2 (12) 0 (0) 1 (20) 0 (0) 4 (12) 0 (0) 
Anemia 0 (0) 0 (0) 1 (14) 0 (0) 2 (12) 0 (0) 1 (20) 0 (0) 4 (12) 0 (0) 
Dyspnea 0 (0) 0 (0) 1 (14) 0 (0) 2 (12) 1 (6) 0 (0) 0 (0) 3 (9) 1 (3) 
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Table 5. Summary of pharmacokinetic parameters 
Dasatinib 
schedule  
(BID dose) Day n 
Cmax (ng/mL) 
Geometric mean 
(CV %) 
AUC (ng•h/mL)  
Geometric mean 
(CV %) 
Tmax (hour) 
Median 
(minimum, 
maximum) 
T1/2 (hour) 
Mean (SD) 
Clo 
(L/h) 
Mean (SD) 
Vz/F 
(L) 
Mean 
(SD) 
5D2 (35 mg)  8 6 25 (99) 85 (73) 1.5 (0.5, 4.0) 3.0 (1.1) 642 (651) 3083 (3866) 
26 4 19 (84) 84 (30) 1.4 (0.5, 1.6) 3.0 (0.9) 433 (146) 1842 (602) 
5D2 (50 mg)  8 3 38 (45) 140 (22) 1.0 (0.5, 3.0) 3.8 (0.6) 402 (74) 2144 (205) 
26 3 43 (100) 158 (4) 0.5 (0.5, 2.0) 4.4 (2.2) 317 (13) 2034 (1052) 
5D2 (70 mg)  8 3 46 (91) 165 (78) 0.5 (0.5, 2.0) 4.9 (1.5) 1188 (1716) 9464 (14175) 
26 4 25 (80) 161(8) 2.0 (1.0, 6.0) 4.3 (1.6) 488 (37) 3649 (94) 
CDD (70 mg)  8 3 78 (90) 245 (57) 1.0 (0.5, 6.0) 4.0 (0.8) 327 (210) 2039 (1715) 
26 3 50 (86) 325 (19)a 3.1 (1.1, 6.1) 2.5 (1.0)a 217 (42)a 739 (162)a 
5D2 (90 mg)  8 5 89 (44) 251 (37) 1.0 (0.5, 4.0) 3.2 (0.7) 438 (311) 1922 (1204) 
26 5 83 (58) 492 (33)b 3.0 (1.0, 8.0) 2.3 (0.7)b 191 (64)b 600 (82)b 
CDD (90 mg)  8 6 52 (84) 204 (68) 1.6 (0.0, 3.1) 4.1 (1.3) 545 (364) 3516 (2894) 
26 5 72 (59) 274 (45) 1.5 (0.5, 5.0) 3.1 (1.2) 409 (360) 2176 (2727) 
CDD (100 mg)  8 12 56 (118) 218 (102) 1.5 (0.5, 3.6) 4.3 (1.7) 667 (538) 4224 (3549) 
26 7 52 (96) 207 (79) 2.0 (0.5, 5.0) 3.20 (1.7) 697 (793) 2740 (2541) 
5D2 (120 mg)  8 5 77 (73) 298 (66) 1.0 (0.5, 2.0) 3.2 (0.8) 511 (326) 2223 (1079) 
26 7 98 (82) 396(74) 1.0 (0.5, 2.0) 3.3 (1.5) 368 (234) 1679 (1145) 
CDD (120 mg)  8 5 131 (48) 526 (49) 0.5 (0.0, 2.0) 3.4 (0.7) 270 (195) 1401 (1336) 
26 1 60 (n/a) 207 (n/a) 1.5 (1.5, 1.5) 2.2 (n/a) 590 (n/a) 1877 (n/a) 
5D2 (160 mg)  8 2 203 (53) 436 (56) 0.8 (0.5, 1.0) 2.7 (0.6) 411 (224) 1523 (549) 
26 1 178 (n/a) 502 (n/a) 1.5 (1.5, 1.5) 2.6 (n/a) 319 (n/a) 1195 (n/a) 
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Abbreviations: Cmax, maximum plasma concentration; AUC, area under the plasma concentration-time curve; CV, coefficient of variation; Tmax, time to 
reach Cmax; T1/2, apparent plasma elimination half-life; n/a, not available. 
an=2; bn=4. 
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Figure 1. Mean plasma concentration time profiles of dasatinib at steady state (Day 26):  
A) 5D2 (5 days on treatment/2 days off treatment) schedule B) CDD (continuous twice-daily) 
schedule. BID = twice-daily dosing 
 
 
 
 
